IPOs & Exits, Explained: The 2026 Field Guide
What ipos & exits covers, why it matters in 2026, and the numbers decision-makers should know.
Budget season has a way of clarifying priorities, and this year the spotlight is on ipos & exits. Public filings, exits, and the reopening public-market window. This explainer sets out what the category actually covers, why it has moved to the center of funding & m&a strategy, and the numbers every decision-maker should have at hand.
What it covers
Public filings, exits, and the reopening public-market window. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Funding & M&A coverage, and its daily developments stream into the live IPOs & Exits feed.
Why it matters in 2026
Consider the current numbers: talkiatry's $210 million Series D anchored mental health's seventh straight year atop the clinical funding charts (our coverage).
Meanwhile, garner Health raised back-to-back rounds reaching a $2.74 billion valuation (our coverage).
Meanwhile, uS digital health startups raised $7.4 billion across 244 deals in H1 2026, with 45% of capital in $100M+ megadeals (our analysis).
What to watch next
Three signals will tell you where ipos & exits goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
For leaders building 2027 plans, this belongs on the shortlist of capabilities to own rather than outsource. For the latest developments, follow our continuously updated IPOs & Exits topic page.